ImmuneOnco submitted application of investigating new drug (IND) IMM40H for clinical research application to the National Medical Products Administration (NMPA)
Date：2022-06-24 Views：355
On June 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that application of investigating new drug (IND) IMM40H for clinical research to the National Medical Products Administration (NMPA) has been officially accepted.
IMM40H is a Humanized anti-CD70 Ig G1 monoclonal antibody newly developed by the company. CD70 highly and widely expresses in many tumor tissues. Its ligand, CD27, expresses on regulatory T (Treg) cells. CD70/CD27 interaction activates Treg cells to induce immune depression.
In vivo preclinical efficacy studies have shown that IMM40H has significant anti-tumor activity against a variety of tumors, especially for multiple myeloma, and 2-3 dosing at a low dosage can completely remove implanted subcutaneous tumors.
Founder, Chairman and CEO of ImmunOnco, Dr. Tian, Wenzhi said:
"I am very pleased that the clinical application of the IMM40H project we newly developed has been accepted by the National Medical Products Administration. We believe that IMM40H has great value for clinical development. We will actively promote the clinical research of this project, and will combine with other projects of the company (IMM01, IMM2510 , IMM47, etc.) for more indications”.
About IMM40H
IMM40H is a humanized IgG1 CD70 antibody independently developed by ImmuneOnco, with high affinity (KD = 3.22x10-11 M) and strong target-blocking activity. In vivo efficacy studies have shown that IMM40H has significant antitumor activity against a variety of tumors, especially for multiple myeloma, and 2-3 dosing at a low dose can completely remove implanted subcutaneous tumors. At the same time, studies in renal cancer models, combination of IMM40H and IMM01 (CD47-blocker) have a good synergistic effect, and the antitumor activity of the combination is significantly superior to that of single-target drugs.